Pediatric Solid Tumor Clinical Trial
Official title:
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors
Phase I dose escalation clinical trial: to explore the dose limiting toxicity (DLT) of mitoxantrone hydrochloride liposome injection in the treatment of children with relapsed and refractory lymphoma and solid tumors. Pharmacokinetics clinical trial: to observe the pharmacokinetics of mitoxantrone hydrochloride liposomes in children with relapsed and refractory lymphoma and solid tumors. To evaluate the safety and efficacy of mitoxantrone hydrochloride liposomes in children with lymphoma and solid tumors.
Status | Recruiting |
Enrollment | 68 |
Est. completion date | June 1, 2025 |
Est. primary completion date | June 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 21 Years |
Eligibility | Inclusion Criteria: - 1. Subjects fully understand and voluntarily participate in this study and sign the informed consent form (ICF); - 2. 2-21 years old; - 3. Expected survival = 3 months; - 4. Subjects with histologically confirmed diagnosis of relapsed and refractory lymphoma and solid tumors, which is one of the following subtypes: 1. Lymphoblastic lymphoma 2. Anaplastic large T cell lymphoma 3. Burkitt's lymphoma 4. Diffuse large B-cell lymphoma 5. Peripheral T, NK/T cell lymphoma 6. Soft tissue sarcoma 7. Neuroblastoma 8. Other subtypes of lymphoma or solid tumors that the investigators believe can be included - 5. Relapsed lymphoma is defined as the lymphoma that relapse after obtaining complete response (CR) after initial chemotherapy; Refractory lymphoma subjects meet one of the following conditions: 1) The tumor shrinks <50% or disease progression after 4 cycles of standard chemotherapy,; 2) CR after standard chemotherapy, but relapse within half a year; 3) 2 or more relapses after CR; 4) relapse after hematopoietic stem cell transplantation; - 6. Lymphoma subjects must have at least one evaluable or measurable lesion per lugano2014 criteria: for lymph node lesions, the length should be > 1.5cm; For non-lymph node lesions, the length should be > 1.0cm; - 7. Solid tumors must have tumor lesions measurable by CT or MRI; - 8. ECOG Performance Status: 0-2; - 9. Bone marrow function: Absolute neutrophil count =1.5×109/L, Platelet count =75×109/L, Hemoglobin = 80g/L (Absolute neutrophil can be relaxed to = 1.0×109/L, Platelet count can be relaxed to =50×109/L, Hemoglobin can be relaxed to =75 g/L in subjects with poor bone-marrow reserve); - 10. Liver and kidney function: serum creatinine = 1.5×ULN (upper limit of normal); AST and ALT = 2.5×ULN (= 5×ULN for subjects with liver metastases); total bilirubin = 1.5×ULN (= 3×ULN for subjects with liver metastases). Exclusion Criteria: - 1. The subject had previously received any of the following anti-tumor treatments: 1. Subjects who have been treated with mitoxantrone or mitoxantrone liposomes; 2. Previously received doxorubicin or other anthracycline treatment, and the total cumulative dose of doxorubicin was more than 360 mg/m2 (1 mg doxorubicin equivalent to 2 mg epirubicin); 3. Subjects who received anti-tumor treatment (including chemotherapy, targeted therapy, glucocorticoid, traditional Chinese medicine with anti-tumor activity, etc.) or participated in other clinical trials and received trial drugs; 4. Subjects who received autologous hematopoietic stem cell transplantation within 100 days after the first medication or allogeneic hematopoietic stem cell transplantation. - 2. Hypersensitivity to any study drug or its components; - 3. Uncontrolled systemic diseases (such as active infection, uncontrolled hypertension, diabetes, etc.); - 4. Heart function and disease meet one of the following conditions: 1. Long QTc syndrome or QTc interval > 480 ms; 2. Complete left bundle branch block, grade II or III atrioventricular block; 3. Serious and uncontrolled arrhythmias requiring drug treatment; 4. New York Heart Association grade = III; 5. Cardiac ejection fraction (LVEF)< 50%; 6. A history of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or ECG evidence of acute ischemia or active conduction system abnormalities within 6 months before recruitment. - 5. Hepatitis B and hepatitis C active infection (plus HBV DNA if one positive for hepatitis B surface antigen or core antibody and HBV DNA more than 1×103 copy/mL excluded; plus HCV RNA if hepatitis C antibody positive and HCV RNA more than 1×103 copy/mL exclude); - 6. Human immunodeficiency virus (HIV) infection (HIV antibody positive); - 7. Subjects with other malignant tumors past or present (except for non-melanoma skin basal cell carcinoma, breast/cervical carcinoma in control, and other malignant tumors that have been effectively controlled without treatment within the past five years); - 8. Subjects suffering from primary or secondary central nervous system (CNS) lymphoma or a history of CNS lymphoma at the time of recruitment; - 9. Pregnant and lactating women and childbearing age patients unwilling to take contraceptive measures; - 10. Unsuitable subjects for this study determined by the investigator. |
Country | Name | City | State |
---|---|---|---|
China | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University | CSPC Ouyi Pharmaceutical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum-tolerated dose | To investigate the safety and preliminary antitumor efficacy | Up to 21 days | |
Primary | peak time (Tmax) | To evaluate the pharmacokinetics of mitoxantrone hydrochloride liposome at different doses in subjects | Up to 18 weeks | |
Primary | Maximum Plasma Concentration (Cmax) | To evaluate the pharmacokinetics of mitoxantrone hydrochloride liposome at different doses in subjects | Up to 18 weeks | |
Primary | Area under the plasma concentration versus time curve (AUC) | To evaluate the pharmacokinetics of mitoxantrone hydrochloride liposome at different doses in subjects | Up to 18 weeks | |
Primary | Elimination half life (t1/2) | To evaluate the pharmacokinetics of mitoxantrone hydrochloride liposome at different doses in subjects | Up to 18 weeks | |
Primary | Incidence and severity of hematological adverse events | To evaluate the incidence and severity of hematological adverse events in patients enrolled in phase Ib | From date of randomization until 4 weeks after the last dose | |
Secondary | Dose limiting toxicities | To investigate the safety | Up to 21 days | |
Secondary | Objective response rate | To investigate the preliminary antitumor efficacy of phase I dose escalation and pharmacokinetics study | Up to 18 weeks | |
Secondary | Complete response rate | To investigate the preliminary antitumor efficacy of phase I dose escalation and pharmacokinetics study | Up to 18 weeks | |
Secondary | Progression free survival | To investigate the preliminary antitumor efficacy of phase I dose escalation and pharmacokinetics study | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 70 weeks | |
Secondary | The incidence and severity of AE and SAE | To identify the incidence and severity of AE and SAE (NCI CTCAE v5.0) | up to 42 weeks unless related serious adverse events need to be recorded indefinitely | |
Secondary | Incidence and severity of non-hematological adverse events | The incidence and severity of non-hematological adverse events were evaluated in patients enrolled in Phase Ib | From date of randomization until 4 weeks after the last dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05151718 -
Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents
|
||
Recruiting |
NCT02787876 -
Pegteograstim in Children With Solid Tumors
|
Phase 2 | |
Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02520713 -
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
|
||
Recruiting |
NCT05468359 -
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04944875 -
Effects of Music and Maternal Voice on Sedation Depth and Sedative Use During Pediatric Magnetic Resonance Imaging.
|
N/A | |
Recruiting |
NCT03618381 -
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
|
Phase 1 | |
Recruiting |
NCT04897321 -
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
|
Phase 1 | |
Completed |
NCT05024331 -
A Prediction Model of Hematological Recovery After High-dose Chemotherapy in Pediatric Solid Tumor
|
||
Active, not recruiting |
NCT04483778 -
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
|
Phase 1 | |
Active, not recruiting |
NCT04239040 -
GVAX Plus Checkpoint Blockade in Neuroblastoma
|
Phase 1 | |
Recruiting |
NCT03739827 -
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
|
||
Recruiting |
NCT02339753 -
Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT03222258 -
Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
|
||
Completed |
NCT02564198 -
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03273829 -
Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed or Refractory Solid Tumors and Leukemias
|
Phase 1 | |
Completed |
NCT03455140 -
A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)
|
Phase 1/Phase 2 | |
Completed |
NCT01853345 -
iCAT for Recurrent/Refractory/HR Solid Tumors
|
N/A | |
Active, not recruiting |
NCT03478462 -
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
|
Phase 1 | |
Not yet recruiting |
NCT05322187 -
Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy
|
Phase 2/Phase 3 |